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AbstrAct
bAckground: Despite the revolutionary success of introducing tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), for treating chronic 
myeloid leukemia (CML), a substantial proportion of patients’ treatments fail.
Aim: This study investigates the correlation between patient adherence and failure of TKIs’ treatment in a follow-up study.
methods: This is a follow-up study of a new cohort of CML patients. Adherence to IM is assessed using the Medication Event Monitoring System 
(MEMS 6 TrackCap, AARDEX Ltd). The 9-item Morisky Medication Adherence Scale, medication possession ratio (MPR) calculation, and the electronic 
medical records are used for identifying potential factors that influence adherence. Clinical outcomes are assessed according to the European Leukemia Net 
2013 guidelines via reverse transcriptase quantitative polymerase chain reaction measurement of the level of BCR-ABL1 transcripts in peripheral blood. 
Response is classified at the hematological, cytogenetic, and molecular levels into optimal, suboptimal, or failure.
results: A total of 36 CML patients (5 citizens and 31 noncitizen residents) consented to participate in the study. The overall mean MEMS score was 
89. Of the 36 patients, 22 (61%) were classified as adherent (mean: 95) and 14 (39%) were classified as nonadherent (mean: 80.2). Adherent patients were 
significantly more likely to obtain optimal response (95%) compared to the nonadherent group (14.3%; P , 0.0001). The rate of poor adherence was as high 
as 39% using MEMS, which correlates with 37% treatment failure rate. The survey results show that 97% of patients increased the IM dose by themselves 
when they felt unwell and 31% of them took the missing IM dose when they remembered. Other factors known to influence adherence show that half of 
patients developed one or more side effects, 65% of patients experienced lack of funds, 13% of patients declared unavailability of the drug in the NCCCR 
pharmacy, and 72% of patients believed that IM would cure the disease. The MPR results reveal that 16% of patients had poor access to treatment through 
the hospital pharmacy.
discussion And conclusion: This is the first prospective study to evaluate CML patients’ adherence and response to IM in Qatar. The high 
rate of treatment failure observed in Qatar is explained by poor adherence. An economic factor (unaffordable drug prices) is one of the main causes of non-
adherence and efforts should be made locally to improve access to medication for cancer diseases. Other risk factors associated with poor adherence could 
be improved by close monitoring and dose adjustment. Monitoring risk factors for poor adherence and patient education that include direct communication 
between the health-care teams, doctors, nurses, pharmacists, and patients are essential components for maximizing the benefits of TKI therapy and could 
rectify this problem. The preliminary results show that patients’ response to treatment may be directly linked to patients’ adherence to treatment. However, 
further in-depth and specific analysis may be necessary in a larger cohort.
keywords: imatinib mesylate, chronic myeloid leukemia, adherence, 9-item Morisky Medication Adherence Scale, medication possession ratio, 
Medication Event Monitoring System, treatment response BCR-ABL1, ABL1, reverse transcriptase quantitative polymerase chain reaction, BCR-
ABL1 mutations
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background
Despite the revolutionary success of introducing tyrosine 
kinase inhibitors (TKIs), such as imatinib mesylate (IM), in 
treating chronic myeloid leukemia (CML), a substantial pro-
portion of CML patients fail treatment with interruption and 
discontinuation of the drug, rapidly leading to reemergence 
from minimal residual disease into full-blown disease.1–11
Adherence to therapy and compliance with professional 
instructions are critical in the management of CML. Compli-
ance is defined by the World Health Organization (WHO) 
report as “the extent to which a patients’ behavior taking 
medication corresponds with agreed recommendations from 
a health-care provider”.12
Several studies suggest that poor adherence to IM is 
frequent and leads to worse clinical outcomes. Noens et al.13 
reported that patients with suboptimal response are signifi-
cantly more likely to miss doses of their IM (23%) than those 
with optimal response (7%). Similarly, Marin et al.14 showed 
that patients with a complete cytogenetic response (CCyR) are 
also less likely to neglect their IM (9%) compared to those 
with an incomplete cytogenetic response (23%). They show 
that the six-year probability of achieving major molecular 
response rates is significantly higher for patients who score 
more than 90% levels of adherence, followed by no complete 
molecular response (adherence #90%) and then no molecular 
responses (MRs; adherence #80%).14
Furthermore, Ibrahim et al.15 showed that the adherence 
rates in patients who eventually fail IM therapy is significantly 
lower (78.1%) than those of patients who respond to therapy 
(97.8%). In their study, patients with an adherence rate #85% 
had significantly lower event-free survival (EFS; 54.4%) than 
adherent patients (EFS rate: 91.4%). In addition, Jonsson et al.16 
showed that 97% of their patients achieved optimal response 
in correlation with optimal adherence. On the other hand, the 
results of a multicenter STop IMatinib Trial by Mahon et al.17 
showed that 61% of patients relapsed after discontinuation 
of IM, and Yhim et al showed that 71% of patients relapsed 
within 9.5 months after discontinuation of IM.14–19
In the first study of our series, we uncovered the mecha-
nisms of resistance in 78% of patients, where two patients had 
BCR-ABL1 kinase domain mutations, one patient had E459K 
(rs1064156), one patient had a unique insertion of three nucle-
otides, six patients had additional chromosomal abnormali-
ties as an underlying mechanism of resistance, four patients 
had no identifiable cause of resistance, and two patients were 
intolerant to treatment. However, 22% of the resistant cases 
displayed no explanatory underlying mechanisms.20,21
Thus, the main aim of this follow-up study is to inves-
tigate the relationship between adherence and failure of IM 
treatment in Qatar. Several methods including Medication 
Event Monitoring System (MEMS 6), 9-item Morisky Medi-
cation Adherence Scale (9-MMAS), medication possession 
ratio (MPR), and electronic medical records (eMR) are used. 
This study gives an insight into whether adherence affects 
patients’ responses to treatment and thus helps deign suitable 
interventions to increase patients’ awareness. As far as the 
author is aware, this is the first study to be conducted among 
patients in the state of Qatar.
design and method
Patient recruitment. Patients aged 16–65 years (mean 
age: 42 years) who attended the NCCCR between January 
2010 and December 2012 with Philadelphia chromosome 
positive (Ph+) CML for at least 12 months and received only 
IM treatment are included in this study. A total of 36 CML 
patients met the inclusion criteria and have consented and 
been recruited into the study.
treatment regimens. Patients in chronic phase (CP) 
received 400 mg orally once a day as first-line treatment 
IM, while accelerated phase (AP) patients received 600 mg 
once a day.
Adherence measures. A holistic approach is taken to 
assess adherence of CML patients to treatment and correlate 
the result with response to treatment (Fig. 1).
Adherence to IM is assessed using the Medication Event 
Monitoring System (MEMS 6 TrackCap, AARDEX Ltd).
In addition, the 9-MMAS, MPR calculation, and eMR 
are used to identify potential factors that influence adherence. 
The presence or absence of nonadherent behaviors is measured 
by the percentage of time a patient has access to medication 
and by reviewing patients’ medication histories. There are four 
methods employed as follows.
Method 1: Medication Event Monitoring System (MEMS). 
Patient adherence over a period of 6–12 months is moni-
tored in real time. The MEMS medication bottles contain a 
microelectronic chip fitted into the cap of a normal-looking 
medication bottle that automatically records and registers 
the date and time of every bottle opening. Each bottle open-
ing is assumed to represent an event of medication intake. 
The system does not monitor the actual dose received; how-
ever, MEMS is considered the gold standard for measuring 
adherence.22,23 A cutoff of less than or equal to 90% is consid-
ered nonadherence.14,22,23
Patients are not notified about the monitoring system in 
the bottle caps but are told that their adherence is going to be 
monitored by counting the number of IM tablets returned.
Method 2: adherence and factors that affect therapy. 
1. 9-MMAS: Our questionnaire consists of two parts; 
the first part is adapted from the well-validated 
Morisky–Green test and the eight-item MMAS.24–28 
The 9-MMAS includes nine items that measure the 
presence or absence of nonadherent behavior, rather 
than dose intake (see Table 1). Responses include either 
yes/no (questions 1–8) or five-point Likert responses 
(question 9). The summary score ranges from 1 to 13, 
where higher scores reflect better adherence. In this 
study, good adherence is defined by a Morisky score of 11 
or higher (ie, $85%).
Outcomes for treating chronic myeloid leukemia
97CliniCal MediCine insights: OnCOlOgy 2016:10
2. In the second part, patients are asked predefined follow-up 
questions to identify potential factors known to influence 
adherence to therapy. These questions revolve around the 
patient’s lifestyle, income, and knowledge related to IM 
factors (eg, degree of social support, knowledge of treat-
ment, and the accessibility of the treating clinic). Patient 
characteristics and demographic data are also collected 
(see Table 2).25,26
Method 3: MPR calculation. MPR is employed to gain 
insight into patients’ access to treatment. The MPR is calcu-
lated by dividing the sum of supply days of medication by the 
number of days between the first fill and the last refill. An 
MPR $ 80% is considered high adherence and is the bench-
mark most commonly reported in the literature.29,30
Method 4: eMR. The eMR is reviewed to gain insight into 
the patients’ medication histories and drug–drug interactions 
using MICROMEDEX® 1.0 (Healthcare Series). Patient 
adherence is correlated with patient’s response treatment 
1
2
3
Correlation Assessment
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responses
• Medication event monitoring system (MEMS)
• 9-item morisky medication adherence scale (9-MMAS)
• Medication possession ratio (MPR) calculation
• Electronic medical records (eMR)
• Electronic medication mointor
• Adherence behaviour
• Factors influence adherence
• Patients′ access to treatment
• Pill counting during refills
• Patients′ medication histories and drug-drug
interactions
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mutations
BCR-ABL1
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4
figure 1. assessment of patients’ adherence and response to iM and correlating with treatment response. 
notes: MeMs electronically monitors medication intake, 9 MMas assesses adherence related behaviors and factors affecting it. On the other hand, MPR 
assesses the access of patient to treatment resources and counts the remaining pills at the time of refills. Finally, eMR examines medication history and 
drug–drug interactions.
Table 1. the 9-item MMas to measure and evaluate adherence to iM.
nInE-ITEM MMAS
1. do you sometimes forget to take medication? y/na
2.  People sometimes miss taking their medications for reasons other than forgetting. thinking over the past 2 weeks, were there 
any days when you did not take your medicine?
y/n
3. have you ever cut back or stop taking your medication without telling your doctor, because you felt worse when you took it? y/n
4. When you travel or leave home, do you sometimes forget to bring along your medicine? y/n
5. did you take your medicine yesterday? y/n
6. do you have a special routine or reminder system to help you take your medications? y/n
7. do you sometimes stop taking your medication if it feels like your disease is under control? y/n
8.  taking medication every day is a real inconvenience for some people. do you ever feel hassled about sticking to your  
treatment plan?
y/n
9. How often do you have difficulty remembering to take all of your medicines? scale 1–5b
note: aQuestions 1–8 are answered by yes or no (y/n). in questions 1–4, 7, and 8, the answer “yes” gives 0 point and “no” gives 1 point. in questions 5–6, the 
answer “yes” gives 1 point and “no” gives 0 point. bQuestion 9 is answered by “never/rarely” (5 points), “once in a while” (4 points), “sometimes” (3 points), “usually” 
(2 points), or “all the time” (1 point).
and response is assessed according to the 2013 European 
LeukemiaNet (ELN) guidelines.
laboratory assessments/assessment of patients’ 
responses. Molecular investigation is carried out to assess 
the degree of response of the 36 patients and classify their 
response according to the ELN 2013. There are four methods 
employed as follows.
Method 1: absolute quantification of BCR-ABL1. Peripheral 
blood samples are collected and the level of BCR-ABL1 tran-
scripts measured locally via reverse transcriptase quantitative 
polymerase chain reaction (RT-QPCR). Patients’ responses to 
treatment are assessed via serial RT-QPCR for absolute quan-
tification of BCR-ABL1 to monitor the ratio of BCR-ABL1 
to normal ABL1 transcripts. The measurement of BCR-ABL1 
is optimized locally according to the international guidelines 
of the Europe against Cancer (EAC). The absolute quanti-
fication of BCR-ABL1 is done using two different kits and 
methods [(1) Ipsogen BCR-ABL1 Mbcr IS-MMR DX and 
(2) Xpert BCR-ABL Monitor™, Cepheid].
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1. The Ipsogen BCR-ABL1 Mbcr IS-MMR DX used in 
this study includes an IS-MMR calibrator, allowing 
conversion of results to the international scale (IS). The 
BCR-ABL1 IS is calculated using this formula.31–34
International Scale – Normalized Copy Number  
(IS-NCN)sample = (NCNsample × International Scale –  
Calibration IS-Cal value)/NCNcal
2. A fully automated cartridge-based assay (Xpert BCR-
ABL Monitor™, Cepheid) combines sample preparation 
with real-time PCR. The results generated are converted 
to the IS using an assay-specific conversion factor deter-
mined by comparison to an IS reference assay.35–41
The MR is determined every third month by analysis 
of the BCR-ABL1 transcript level in peripheral blood (RT-
QPCR) with ABL1 as a housekeeping gene. The BCR-ABL1 
is reported in the IS37 as well as described elsewhere.20,21
Method 2: assessment of patients’ responses. The ELN 2013 
recommendations for the management of CML is adopted 
and employed in this study to assess the response/resistance 
of patients to treatment. Responses are defined at the hemato-
logical, cytogenetic, and molecular levels. Patients’ responses 
are classified as optimal, suboptimal, or failure.42
Method 3: BCR-ABL1 mutations. Sequencing of tyrosine 
kinase domain of BCR-ABL1 is carried out to identify muta-
tions as an underlying mechanism of resistance.
Sequencing reactions are performed in the forward and 
reverse directions separately using Big Dye chain termina-
tor reagents on an ABI PRISM 3130 Genetic Analyzer, as 
described elsewhere.21
Method 4: karyotype analysis and fluorescence in situ hybrid-
ization (FISH). Conventional karyotyping is carried out to 
identify ACAs as an underlying mechanism of resistance.
Chromosomes are identified and arranged according to 
the International System for Human Cytogenetic Nomencla-
ture 2009. The number of cells investigated for each patient 
at each analysis ranges from 20 to 30 metaphases, and the 
cytogenetic response is assessed according to the ELN criteria. 
Cytogenetic analysis of metaphases of bone marrow samples 
as well as FISH for BCR-ABL on interphases of peripheral 
100–200 white blood cells is done routinely as part of the 
clinical protocol, and the results are reported on the hospital’s 
health information system.
ethics. Patients gave their written informed consent 
to participate in the study that was conducted in accordance 
with the principles of the Declaration of Helsinki and was 
approved by Hamad Medical Corporation Research Commit-
tee [HMC (GC-1013)]. All data and patients’ identities were 
stored anonymously, and only the principal investigator has 
access to the code key. Thus, individual results were not seen 
by the treating physician.
statistical analysis. Descriptive statistics (means, 
ranges, frequencies, and percentages) were shown for each 
measure accordingly. Pearson correlation was used to investi-
gate the relationship between the three adherence techniques 
(MMAS, MPR, and MEMS). In addition, Fisher’s exact test 
was performed to study patients’ adherence and responses and 
the factors that affect them. A significance level of P # 0.05 
(two tailed) was considered. GraphPad Prism 5 statistical 
package was used for analysis.
results
demographic features results. Of the 36 patients, 28 
(78%) were male and 8 (22%) were female, with more than 
half (N: 21; 59%) having an educational level of secondary 
school or less. A total of 27 patients (75%) were married while 
9 patients (25%) were single. Patients were from 12 different 
countries with only 5 Qatari patients (13%; Table 3).
The clinical presentation of the 36 CML patients at diag-
nosis was as follows: 89% (32 patients) CP, 9% (3 patients) AP, 
and 3% (1) blastic crisis phase (BCP). A total of 35 patients 
were alive and one patient had died (Table 4).
A total of 32 patients were treated with standard dose 
IM 400 mg, while 4 patients were treated with 600 mg due to 
Table 2. Potential factors that influence adherence to therapy.
1. age years
2. year of diagnosis date
3. Marital status MCQ
4. level of education MCQ
3. year of starting glivec (imatinib) treatment? date
4. how much do you know about CMl? scale 1–4
5. When did you receive the majority of this knowledge/information? MCQ 
6. Who gave you most of this knowledge/information? MCQ 
7. how much do you know about tour treatment? scale 1–4
8. When did you receive the majority of the knowledge/information about your treatment? MCQ 
9. Who gave you the majority of this knowledge/information about your treatment? MCQ
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a history of either loss of complete cytogenetic response 
(CCyR; n = 1) or suboptimal MR (n = 3).
Method 1: MEMS results. The overall mean MEMS score 
was 89.0% (range: 40–100). Of the 36 patients, 22 (61%) were 
classified as adherent patients (mean: 95%; range: 91%–100%) 
and 14 (39%) were classified as nonadherent patients (mean: 
80.2%; range: 40%–90%).
Adherent patients were significantly more likely to achieve 
optimal response [95% (21/22)] compared to the nonadherent 
group [14.3% (2/14); P , 0.0001; odds ratio (OR): 126, 95% 
confidence interval (CI): 10.3–1541; Table 5 and Fig. 2].
Method 2: adherence and factors that affect therapy. 
1 9-item MMAS results: The overall mean Morisky 
score of the 36 patients was 10.6 (range: 5–13). Of the 
36 patients, 25 patients (69%) were classified as adher-
ent (MMAS mean: 12; range: 11–13) and 11 patients 
(31%) were nonadherent (MMAS mean: 7.7; range: 
5–10; Table 6).
The 9-MMAS revealed that 14 patients (38%) missed 
medication sometimes, 5 patients (14%) stopped taking their 
medication when they felt that the disease was under control or 
found sticking to treatment plan difficult. All patients (100%) 
had a special routine or reminder system to help them take 
medication on time, and 13 patients (36%) sometimes had dif-
ficulty remembering to take all their medicines.
Adherent patients were more likely to achieve optimal 
response (72%; 18/25) compared with the nonadherent group 
(45.5%; 5/11). However, this difference was not significant.
2. Patients’ behavior and knowledge about intake of IM 
results: A total of 32 patients (89%) took the IM after 
meals and 4 patients (11%) took the medication with 
grapefruit, while 4 patients (11%) took IM on an empty 
stomach. One patient (3%) increased the IM dose with-
out consultation with their GP when they felt unwell. 
A total of 11 patients (31%) took the missing IM dose 
when they remembered, while 12 (33%) did nothing for 
missing dose (Table 7).
A total of 18 patients (50%) developed one or more side 
effects such as fatigue, nausea, vomiting, headache, muscle 
pain, abdominal pain, skin rash/itching, orbital edema, leg 
edema, memory change, sunburn, weight gain, or infection 
(muscle pain and skin rashes accounted for 35% and 29% of 
the side effects, respectively).
Interestingly, 23 patients (74%) experienced lack of funds. 
However, these patients were offered the medicine completely 
free with the support of the hospital social services depart-
ment, and five patients (13%) declared the unavailability of the 
drug in the NCCCR pharmacy. A total of 26 (72%) patients 
believed that IM would cure the disease (Table 8).
Table 9 shows how IM works, why and how to take IM, 
and information about the side effects of IM.
Table 3. demographic features of the 36 patients (survey 
questionnaire).
vARIABLE vALuE (nuMBER) PERCEnTAgE %
gender
Males 28 78%
Females 8 22%
age, years average 
(Min-Max)
42 (16–65)
Marital status
Married 27 75%
single 9 25%
Level of education
Primary 11 31%
secondary 10 28%
diploma 2 5%
College 11 31%
Master 2 5%
Allergy 
na 36 100%
nationality
Qatar 5 13%
egypt 7 19%
Philippines 5 14%
india 5 14%
sudan 4 11%
Pakistan 3 8%
nepal 2 5%
Bangladesh 2 5%
sri lanka 1 3%
Palestine 1 3%
note: distribution of patients according to gender, age group, marital status, 
level of education, and their ethnic backgrounds.
Table 4. Clinical features/characteristics of the 36 patients.
ChARACTERISTICS TOTAL (%)
Clinical presentation at diagnosis
CP 32 (89%)
aP 3 (9%)
BCP 1 (3%)
IM dose at diagnosis
400 mg 32
600 mg 4
Switched to second line of treatment
dasatinib 9
nilotinib 2
dasatinib then nilotinib 1
alive 35 (97%)
dead 1 (3%)
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It is important to note that in-depth interviews with 
treating physicians revealed that two patients were not adher-
ent to treatment, although it was reported in their survey ques-
tionnaire that they were. There was no significant difference 
between male and female patients (P = 0.17), level of education 
(illiterate, up to secondary school versus graduation and above; 
P = 0.30), married versus singles (P = 0.25), patients with or 
without side effects (P = 0.39), lack of funds (P = 1), or patients’ 
education, using the 9-item MMAS (P = 1; Table 10).
Method 3: MPR results. Of the 36 patients, 4 managed to 
obtain the IM at home. The mean of the overall MPR results 
for the 32 patients was 94% (range: 56.6–100).
figure 2. Patients’ adherence to iM using MeMs.
Table 5. Patients’ response according to adherence status using the MeMs technique.
TEChnIQuES AdhEREnCE RESPOnSE TOTAL P vALuE OddS RATIO (95% COnfIdEnCE InTERvAL)
OPTIMAL n (%) fAILuRE n (%)
MeMs adherent 21 (95%) 1 (5%) 22 ,0.0001 126.0 (10.30–1541)
nonadherent 2 (14.3%) 12 (85.7%) 14
 
Table 6. Patients’ response according to adherence status using the 9-MMas technique.
TEChnIQuES AdhEREnCE RESPOnSE TOTAL P vALuE OddS RATIO (95% COnfIdEnCE InTERvAL)
OPTIMAL n (%) fAILuRE n (%)
9-item MMas adherent 18 (72%) 7 (28%) 25 0.125 3.086 (0.70 −13.47)
nonadherent 5 (45.5%) 6 (54.5%) 11
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Of the 32 patients, 27 (84%) were classified as adherent 
(MPR mean: 96%; range: 84.9%–100%) and 5 (16%) were 
classified as nonadherent (MPR mean: 57.8%; range: 56.6%–
59.0%; Table 11).
The adherent patient group was significantly more likely 
to have optimal response (74%; 20/27) than the nonadher-
ent patient group (20%; 1/5; P = 0.037; OR: 11.43, 95% CI: 
1.1–120.4; Table 11).
Method 4: eMR results. No drug–drug interactions were 
identified using MICROMEDEX® 1.0 (Healthcare Series).
The relationship between the three techniques: Pearson 
correlation was performed for the three techniques (MMAS, 
MPR, and MEMS). There was a significant high positive corre-
lation between MPR and MEMS (r = 0.74; P = 1.053373e−006), 
MMAS and MEMS (r = 0.66; P = 3.547150e−005), and MPR 
and MMAS (r = 0.5; P = 0.0036).
Patients’ response. Of the 36 patients, 23 (63%) 
responded optimally and 13 (37%) failed the treatment.
Those who responded optimally had complete hemato-
logical response, CCyR, and deep MR.
Of the 23 patients who responded optimally, 22 were 
from CP and 1 was from AP according to their initial diagno-
sis, and thus, patients’ initial disease phase (CP, AP, and BCP) 
could be attributed to the treatment outcomes.
It is important to note that achieving early-stage treat-
ment targets is more likely to have better long-term outcomes. 
This study found that of the 23 patients who responded opti-
mally, 22 achieved early-stage treatment and these patients 
continued to have optimal response.
On the other hand, in total, 13 patients failed treatment, 
12 were resistant, and 1 (P25) showed intolerance. Of the 12 
resistant cases, 1 patient (P14) showed both E459K mutation 
Table 7. Patients behavior about iM intake and knowledge-based 
questions.
vARIABLE vALuE (nuMBER) PERCEnTAgE %
IM intake
after meal 32 89
empty stomach 4 11
grapefruit intake
yes 4 11
no 32 89
Increasing dose of Imatinib
yes 1 3
no 35 97
Action if missing dose
nothing 12 33
double the dose 1 3
Wait for next day 12 33
take it same time when  
remembering
11 31
 
Table 8. side effects due to intake of iM.
vARIABLE vALuE (nuMBER) PERCEnTAgE %
Side effects
yes 18 50
no 18 50
Side effects reported
Fatigue 2 12
nausea 2 12
Vomiting 3 18
headache 2 12
Muscle pain 6 35
abdominal pain 1 6
skin rash/itching 5 29
Orbital edema 2 12
leg edema 3 18
Memory change 1 6
sun burn 1 6
Weight gain 1 6
infections 2 12
thrombocytopenia 1 6
Lack of fund*
yes 23 74
no 8 26
non-availability of Imatinib
yes 5 13.9
no 31 86.1
Education about Imatinib
yes 34 94.4
no 2 5.6
By:
Physicians 18
Physicians and nurses 2
Physicians and Online  
resources
1
Physicians/Pharmacist/nurse 1
Physicians and Pharmacists 10
Pharmacist 2
none 2
Believe in cure
yes 26 72
no 10 28
note: *Excluding five Qatari patients as the IM is free of charge for citizens 
while non-citizen residents pay the remaining 10% of IM, which is uncovered 
by the hospital.
and ACAs, 3 patients (P6, P20, and P24) had ACAs, and all 
IM failed patients switched to the second line of treatment, 
either dasatinib or nioltinib.
Long-term disease progression or survival rates upon IM 
treatment showed that of the 36 patients, only 1 (P25) (2.8%) 
was deceased, and this patient was known to have primary 
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Table 10. Comparison of categorical variables with adherence using the 9-item MMas.
vARIABLES AdhEREnCE CATEgORY TOTAL P vALuE
nOnAdhEREnT n (%) AdhEREnT n (%)
sex Female 4 4 8 0.17
Male 7 21 28
level of education illiterate up to secondary school 7 12 19 0.3
graduation and above 4 13 17
Marital status Married 8 22 30 0.25
singles 3 3 6
side effects no 4 12 16 0.39
yes 7 13 20
lack of fund no 4 9 13 1
yes 7 16 23
Patients’ education none and some 1 2 3 1
good and excellent 8 20 28
 
Table 11. Patients’ response according to adherence status using the MPR technique.
TEChnIQuES AdhEREnCE RESPOnSE TOTAL P vALuE OddS RATIO (95% COnfIdEnCE InTERvAL)
OPTIMAL n (%) fAILuRE n (%)
MPR* adherent 20 (74%) 7 (25%) 27 0.0370 11.43 (1.1–120.4)
nonadherent 1 (20%) 4 (80%) 5
note: *the total number of patients were assessed via MPR is 32 as 4 patients were excluded in the MPR analysis because their medications were obtained in their 
own countries.
Table 9. Quality of educational information provided to the patients.
STATEMEnT nOnE SOME gOOd ExCELLEnT
how imatinib works 7 (19.4%) 2 (5.6%) 18 (50.0%) 9 (25.0%)
Why to take the medicine 5 (13.9%) 2 (5.6%) 18 (50.0%) 11 (30.6%)
how to take it 6 (16.7%) 1 (2.8%) 14 (38.9%) 15 (41.7%)
side effects 7 (19.4%) 3 (8.3%) 13 (36.1%) 13 (36.1%)
 
resistance to all TKIs. None of the 36 patients progressed, and 
35 (97.2%) survived (Supplementary Table 1).
discussion and conclusion
This is the first prospective study to evaluate CML patients’ 
adherence and response to IM in Qatar. The rate of treatment 
failure of CML patients treated with IM in Qatar has been 
previously reported to be high (54%).20,21 Due to this high 
rate of IM failure in Qatar, patient’s adherence to treatment 
was studied by observing a new cohort of 36 CML patients. 
One-third of the patients (N: 14, 39%) were classified as non-
adherent and 13 patients (37%) failed treatment. Thus, poor 
adherence explains the high rate of treatment failure observed. 
Nonadherence to the treatment was one of the most common 
causes of IM failure in the patient cohort, documented in 39% 
of cases using the gold standard method (MEMS), which 
seems to be consistent with international data, indicating 
nonadherence rates between 25% and 50%.43 Economic fac-
tors (eg, unaffordable drug prices) were one of the main causes 
of nonadherence. Efforts should be made locally to improve 
access to medication for cancer diseases or through participa-
tion in patient assistance programmes such as Glivec Inter-
national Patient Assistance Programme (GIPAP), which 
provides Glivec free of cost to eligible patients in develop-
ing countries who meet specific medical and socioeconomic 
guidelines. Briefly, GIPAP helps patients who are not insured, 
not reimbursed, cannot pay for treatment privately, and are 
in developing countries that have minimal reimbursement 
capabilities,44 or using generic IM that has been available in 
the market since February 2016 which could reduce the cost 
burden  of treatment. Other risk factors associated with poor 
adherence can be improved by close monitoring and dose 
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adjustment. Monitoring risk factors for poor adherence in 
combination with patient education that includes direct com-
munication between the health-care teams (ie, doctors, nurses, 
and pharmacists) and patients are essential components for 
maximizing the benefits of TKIs and could rectify this prob-
lem. The preliminary results show that patients’ responses to 
treatment may be directly linked to patients’ adherence to the 
treatment. However, further in-depth and specific analysis 
may be necessary in a larger cohort.
In several studies, such as a Belgian study that included 
169 patients, adherence to IM treatment was assessed via 
questionnaires, interviews, and pill counts. A total of 30% of 
the patients were shown to be nonadherent, and only 14% of 
the patients took the prescribed IM dose.13 In a study from the 
United Kingdom, 26% of the patients were shown to be non-
adherent.14 In a follow-up study, the most common reason for 
intentional nonadherence was side effects, and the most com-
mon reason for unintentional nonadherence was forgetful-
ness.45 In a Taiwanese study, Chen et al.19 showed that 26.9% 
of patients showed poor adherence to IM. In these three stud-
ies, in Belgium, Britain, and Taiwan, a relationship between 
nonadherence and treatment response was observed, which is 
consistent across the studies.14,19,45 Chen et al.46 also showed 
in another study that Taiwanese CML patients were adherent 
to IM and reported that adverse drug effects and associated 
polypharmacy were the main and key reasons and concerns 
influencing their adherence to long-term use of IM.
Interestingly, in a Swedish study, Jonsson et al.16 showed 
that 97% (37) of CML patients were classified as adherent and 
all patients optimally responded to treatment.
Nonadherence and treatment interruptions both lead to 
undesired clinical outcomes and appear to be more prevalent 
than previously believed or expected.
There are some limitations to the study. MMAS is a 
subjective method and is the least reliable of the methods. 
However, a questionnaire survey is able to identify indi-
vidual patient’s concerns and subsequently tailor appro-
priate intervention.
Certainly, the disadvantages of such approaches should 
not be underestimated. Relatively poor sensitivity and speci-
ficity can occur due to false data input by patients, acci-
dently or purposefully, or imperfect communication skills 
and questions constructed by interviewers or in the design of 
the survey.
Negativity in questions, suggesting blaming patients 
for not fulfilling their prescribed regime, may lead to bias. 
Patients’ psychological state can impact their answers to 
the questionnaire.
Physicians, nurses, and pharmacists need to educate 
patients and closely monitor their adherence to treatment. 
Improving adherence and limiting treatment interruptions 
would optimize clinical outcomes and reduce the burden of 
disease, and therefore should be assessed routinely as they are 
correlated with poor response to treatment.
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